Pulmonary Hypertension Clinical Trial
Official title:
Implementation and Effect of Exercise and Respiratory Training on 6-minute Walking Distance in Patients With Severe Chronic Pulmonary Hypertension: a Randomized Controlled Multicenter Trial in European Countries
Chronic pulmonary hypertension (PH) is associated with impaired exercise capacity, quality of
life and right ventricular function. The disease is characterized by an increase of pulmonary
vascular resistance and pulmonary arterial pressure, leading to right heart insufficiency.
Despite optimized combination-medical therapy most patients remain symptomatic, have reduced
exercise capacity, quality of life and reduced survival rates, with an annual mortality rate
of approximately 5 -15 % or even higher.
Previous training studies have suggested that exercise training as add-on to medical
treatment is highly effective improving exercise capacity, quality of life and symptoms.
The current guidelines recommend exercise training only in specialized centres including both
PH and rehabilitation specialists who are experienced in exercise training of severely
compromised patients.
A specialized PH-training program has been performed in Heidelberg since 2003 including >1200
patients with various forms of chronic PH. The exercise training program is performed in a
special setting with an in-hospital start of the rehabilitation program. It is characterized
by a low-dose closely supervised exercise training in small groups with additional
psychological support and mental training.
This training program for patients with PH will be implemented in European centers to add
exercise training to the existing PH therapies. The effect of the training on physical
exercise capacity will be assessed by 6-minute walking distance (6-MWD). Further clinical
parameters will be assessed to evaluate the effect on exercise capacity, quality of life and
symptoms.
The aim of this study is to guide European PH-centers to become specialized centers for
training in PH.
126 patients will be included, who either receive exercise training or continue their daily
sedentary life style (1:1 randomization) for 15 weeks.
As inpatient settings are not available in all healthcare systems the training program will
be adapted from the specific training program for PH patients developed in Heidelberg to a
procedure, which is feasible in the local participating centres. Another objective of this
study is to assess if the particular adopted training program specified for each
participating centre and country is still safe and effective.
Pulmonary hypertension (PH) is defined as a mean pulmonary arterial pressure ≥25 mmHg. PH is
often diagnosed at an advanced stage (WHO functional class III-IV) with a massive increase of
the mean pulmonary arterial pressure. A crucial parameter determining the symptoms and
prognosis of the patients is the cardiac reserve. This parameter is defined by the pulmonary
vascular resistance and the right ventricular adaptation. Severe PH is characterized by a
decreased cardiac output at rest, an increased afterload and consecutive cor pulmonale.
Within the last years there has been a huge progress in the scientific fields of genetics,
pathogenesis, pathophysiology and therapy of PH. This has also been documented in the PH
world conferences. New disease-targeted medication has been developed such as endothelin
receptor antagonists (bosentan, ambrisentan, sitaxentan, macitentan), prostacyclin derivates
(inhaled and intravenous iloprost, epoprostenol, treprostinil),
phosphodiesterase-5-inhibitors (sildenafil, tadalafil) and the soluble guanylate cyclase
inhibitor riociguat. Despite these advances in treatment, the disease may not be treated
causally or even be cured. In most cases however, disease progression may be slowed down. The
use of PH-targeted treatment and supporting therapies such as anticoagulation and diuretics
improve the symptoms and impede the progression of the disease. Nevertheless, the prognosis
of the patients remains impaired. The first randomized controlled study investigating the
effect of exercise training in PH showed a significant improvement of exercise capacity and
quality of life. Further uncontrolled trials using a low-dose exercise and respiratory
therapy in different etiologies of PH showed an improvement in exercise capacity, quality of
life, muscle function and further prognostic parameters. A recent randomized controlled study
could support these findings. Studies also showed an improvement in muscle capillarization of
the quadriceps muscle.
The training program consists of interval ergometer training, respiratory therapy, muscle
training and mental gait training. The interval ergometer training allows performing aerobic
exercise training with a low cardio-circulatory stress. In patients with left heart
insufficiency, this training has been successfully implemented. Respiratory therapy has been
established in the rehabilitation of patients with lung disease within the last years. The
different techniques aim to improve ventilation, strengthen the respiratory muscles, mobilize
the thorax and enhance secretolysis. The training program also contains mental (gait)
training. This training was adapted from mental imagery techniques used by sport
psychologists in professional athletes. Mental imagery techniques have shown to improve
physical and cognitive functions.
Due to the beneficial results, exercise training and rehabilitation has received a 1A
recommendation at the PH world symposium in Nice in 2013. This decision was mainly based on
three randomized controlled trials that investigated a limited number of patients. To
unequivocally demonstrate safety and positive effects of exercise training in different
settings large multicenter RCTs are essential. An exercise program has not yet been
implemented in most European countries, partly due to limited access to rehabilitation
programs and institutions.
The aim of this large, multicenter, prospective, randomized controlled trial is to
investigate the effect of exercise training and rehabilitation on physical exercise capacity
across different European countries. Physical exercise capacity will be measured by exercise
induced change of 6-minute walking distance (6-MWD) compared to baseline and the control
group without training. As inpatient settings are not available in all healthcare systems the
training program will be adapted from the specific training program for PH patients developed
in Heidelberg in a system, which is feasible for the local participating centres. Another
objective of this study is to assess if the adopted training program specified for each
participating centre and country is still safe and effective.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT01950585 -
Hydroxyurea in Pulmonary Arterial Hypertension
|
Early Phase 1 | |
Completed |
NCT00527163 -
Role of Nitric Oxide in Malaria
|
||
Completed |
NCT03649932 -
Enteral L Citrulline Supplementation in Preterm Infants - Safety, Efficacy and Dosing
|
Phase 1 | |
Recruiting |
NCT04554160 -
Arrhythmias in Pulmonary Hypertension Assessed by Continuous Long-term Cardiac Monitoring
|
||
Enrolling by invitation |
NCT03683186 -
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
|
Phase 3 | |
Completed |
NCT01894035 -
Non-interventional Multi-center Study on Patients Under Routine Treatment of Pulmonary Arterial Hypertension (PAH) With Inhaled Iloprost Using I-Neb as a Device for Inhalation
|
||
Not yet recruiting |
NCT04083729 -
Persistent Pulmonary Hypertension After Percutaneous Mitral Commissurotomy
|
N/A | |
Terminated |
NCT02243111 -
Detecting Pulmonary Arterial Hypertension (PAH) in Patients With Systemic Sclerosis (SSc) by Ultrasound
|
N/A | |
Terminated |
NCT02246348 -
Evaluating Lung Doppler Signals in Patients With Systemic Sclerosis (SSc)
|
N/A | |
Completed |
NCT02821156 -
Study on the Use of Inhaled NO (iNO)
|
N/A | |
Completed |
NCT02216279 -
Phase-II Study of the Use of PulmoBind for Molecular Imaging of Pulmonary Hypertension
|
Phase 2 | |
Recruiting |
NCT01913847 -
Safety and Efficacy Study of HGP1207 in Patients With Pulmonary Hypertension
|
Phase 3 | |
Completed |
NCT06240871 -
Contrast Enhanced PA Pressure Measurements
|
||
Completed |
NCT01615484 -
Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
|
N/A | |
Completed |
NCT02377934 -
Evaluation of Radiation Induced Pulmonary Hypertension Using MRI in Stage III NSCLC Patients Treated With Chemoradiotherapy. A Pilot Study
|
||
Recruiting |
NCT01091012 -
Effectiveness of the Vasodilator Test With Revatio, Made in Patients With Acute Pulmonary Hypertension
|
Phase 3 | |
Completed |
NCT00739375 -
The Effect of Blood Flow in the Maturing Arteriovenous Access for Hemodialysis on the Development of Pulmonary Hypertension.
|
Phase 1 | |
Completed |
NCT02275793 -
The Regulation of Pulmonary Vascular Resistance in Patients With Heart Failure
|
||
Completed |
NCT01484899 -
Smoking: a Risk Factor for Pulmonary Arterial Hypertension?
|
N/A | |
Completed |
NCT01463514 -
Noninvasive Determination of Cerebral Tissue Oxygenation in Pulmonary Hypertension
|
N/A |